The Impact of Myo- inositol supplementation to prevent gestational diabetes in overweight pregnant women

Determine the effect of myo_inositol supplementation to prevent gestational diabetes in overweight pregnant women.

114 pregnant women who are referred to the obstetric clinics are selected. The participants were divided With a block size of 4, into two groups of A and B by selecting the number of (0 - 6) are randomly assigned.

The participants, if the fasting glucose is less than 92 mg / dl or randomized glucose is less than 200, and other conditions for entry into the study are included.Triglyceride, cholesterol, LDL, HDL, fasting blood sugar , fasting insulin, insulin sensitivity are checked according to routine laboratory tests and then them randomly divided into two groups. In group A (n = 30), people treated with myo-inositol of folic acid once a day from the gestational age of and the group B (n = 30) are received placebo.

Inclusion criteria: Written consent, pregnant women with singleton pregnancy, age above 18 years old, gestational age 14 weeks, per-pregnancy BMI >= 25 and less than 30 kg /m2, fasting glucose less than 92 mg /dL or Random glucose less than 200 mg /dL, no chronic diseases, non-smoking and alcohol. Exclusion criteria: The death experience of one of the first-degree relatives during pregnancy, treatment with corticosteroid during pregnancy.

Intervention group: Myo-inositol containing 2000 mg of myo-inositol and 200 μg of folic acid (manufactured by the company Lo.Li Pharma ) once a day from the gestational age of 14 weeks to 24 weeks Control group: Placebo (folic acid powder 400 mcg + wheat flour total 2 grams) once a day from the gestational age 14 weeks to 24 weeks

primary outcome: Gestational diabetes mellitus (Abnormal oral glucose tolerance test). Secondary outcomes: Neonatal and pregnancy outcomes and side effect of drug

Revising sentence errors

Babol University of Medical Sciences,Governmental

Blocked randomization With a block size of 4, for two groups (A, B). Random numbers (0 - 6) was generated using computer software.

Blind groups include: participant, clinical caregiver, researcher, outcome evaluator, data analyst. Double blind study. Medications and placebo are coded by someone other than the investigator as group (1 and 2) and the investigator do not know which group is related to the drug. The subjects are satisfied and informed that they may be Instead of medication, placebo is given to them. The distribution method With a block size of 4, for two groups (A, B). Random numbers (0 - 6) was generated using computer software.